PMID- 28656510
OWN - NLM
STAT- MEDLINE
DCOM- 20180723
LR  - 20181113
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
VI  - 49
IP  - 11
DP  - 2017 Nov
TI  - Alprostadil protects type 2 diabetes mellitus patients treated with metformin 
      from contrast-induced nephropathy.
PG  - 2019-2026
LID - 10.1007/s11255-017-1639-2 [doi]
AB  - PURPOSE: Type 2 diabetes mellitus (T2DM) patients treated with metformin are 
      predisposed to develop contrast-induced nephropathy (CIN) after received 
      emergency contrast-enhanced computed tomography (CT) examination. We evaluated 
      the protective effects of alprostadil on CIN in T2DM patients treated with 
      metformin after contrast media (CM) administration. METHODS: In this 
      single-institution, single-blind, superiority trial, we randomly assigned 451 
      T2DM patients taking metformin and underwent emergency contrast-enhanced CT 
      examination to either the alprostadil group (227 patients) receiving alprostadil 
      or the control group (224 patients) without alprostadil. All subjects stopped 
      taking metformin and drank 500 ml water within 12 h after CM exposure. In 
      addition, patients in the alprostadil group were injected with alprostadil 
      (10 mug/day, for 3 days) plus 20 ml normal saline (alprostadil hydration) and the 
      control group patients were daily injected with 20 ml normal saline as control 
      for 3 days following CM administration. Serum creatinine (Scr) was measured 
      before and <72 h after contrast-enhanced CT examination. CIN was defined as an 
      increase in Scr >/= 44.2 micromol/l (0.5 mg/dL) or >25% over baseline within 3 days of 
      contrast administration. RESULTS: There was a lower incidence of CIN in patients 
      underwent alprostadil hydration than drinking water monohydration after CM 
      administration, who with either normal renal function or chronic kidney disease 
      (baseline eGFR < 60 ml.min(-1).1.73 m(-2)). CONCLUSIONS: Alprostadil hydration 
      was superior to drinking water monohydration regarding preventing CIN in T2DM 
      patients treated with metformin after contrast-enhanced CT.
FAU - Wang, Jing
AU  - Wang J
AD  - The Department of Endocrinology and Metabolism, The Affiliated Hospital of 
      Qingdao University, Qingdao, 266100, China.
FAU - Ai, Xiaobo
AU  - Ai X
AD  - Department of Nephrology, Qingdao Fifth People's Hospital, Qingdao, 266000, 
      China.
FAU - Li, Li
AU  - Li L
AD  - The Department of Endocrinology and Metabolism, The Affiliated Hospital of 
      Qingdao University, Qingdao, 266100, China.
FAU - Gao, Yanyan
AU  - Gao Y
AD  - The Department of Endocrinology and Metabolism, The Affiliated Hospital of 
      Qingdao University, Qingdao, 266100, China.
FAU - Sun, Nina
AU  - Sun N
AD  - Department of Respiratory Medicine, The Affiliated Hospital of Qingdao 
      University, Qingdao, 266100, China.
FAU - Li, Changgui
AU  - Li C
AD  - Gout Laboratory, The Affiliated Hospital of Qingdao University, Shandong 
      Provincial Key Laboratory of Metabolic Diseases, QingdaoUniversity, Qingdao, 
      266100, China. lichanggui@medmail.com.cn.
FAU - Sun, Weihong
AU  - Sun W
AD  - Biotherapy Center, The Affiliated Central Hospital of Qingdao University, 
      Qingdao, 266042, China. sunweihong@126.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170627
PL  - Netherlands
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
RN  - 0 (Contrast Media)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Urological Agents)
RN  - 9100L32L2N (Metformin)
RN  - AYI8EX34EU (Creatinine)
RN  - F5TD010360 (Alprostadil)
SB  - IM
MH  - Aged
MH  - Alprostadil/*therapeutic use
MH  - Contrast Media/*adverse effects
MH  - Creatinine/blood
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Emergencies
MH  - Female
MH  - Fluid Therapy
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Kidney Diseases/blood/*chemically induced/*prevention & control
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Single-Blind Method
MH  - Tomography, X-Ray Computed
MH  - Urological Agents/*therapeutic use
OTO - NOTNLM
OT  - Alprostadil
OT  - Contrast media
OT  - Contrast-induced nephropathy
OT  - Diabetes mellitus
OT  - Metformin
EDAT- 2017/06/29 06:00
MHDA- 2018/07/24 06:00
CRDT- 2017/06/29 06:00
PHST- 2016/08/26 00:00 [received]
PHST- 2017/06/19 00:00 [accepted]
PHST- 2017/06/29 06:00 [pubmed]
PHST- 2018/07/24 06:00 [medline]
PHST- 2017/06/29 06:00 [entrez]
AID - 10.1007/s11255-017-1639-2 [pii]
AID - 10.1007/s11255-017-1639-2 [doi]
PST - ppublish
SO  - Int Urol Nephrol. 2017 Nov;49(11):2019-2026. doi: 10.1007/s11255-017-1639-2. Epub 
      2017 Jun 27.